UCB agreed to acquire Neurona Therapeutics for up to $1.15 billion, with $650 million paid upfront and the remainder tied to milestones. The deal targets epilepsy through Neurona’s lead asset NRTX-1001. The acquisition arrives amid an active wave of neurology transactions in 2026, as big pharma expands its toolkits across seizure disorders and other CNS diseases where late-stage or platform bets can be difficult to source internally. For Neurona and UCB, the immediate focus becomes regulatory and clinical execution around NRTX-1001 while integrating the development roadmap into UCB’s broader neuroscience pipeline.